FirstWord

FirstWord is a major healthcare intelligence provider worldwide. The customers are offered upscale reports on various sectors of pharmaceutical industry. Research is carried out by best specialists in pharma market who ensure the clients with unique data, deep insight into the issue, latest events and new technologies.

The experts have access to reliable and abounding data resources to perform qualitative and extensive pharma reports. The area under study involves: biosimilars, medications, orphan drugs, patient-centric disease treatment and healthcare technologies.

In the reports customers will find basic market information on the products and the following takeaways:
  • Leading and emerging trends;
  • Medical enterprises;
  • Critical analysis for best strategies;
  • Multichannel marketing modelling to guide the customers to the right channels and content;
  • Key success factors and opportunities for pharma industry;
  • Pharma sales analysis; etc.
FirstWord helps you stay competitive, get 5 year forecast and improve productive efficiency. To acquire measurable and sufficient outcome it is vital to use FirstWord consulting service.

Research Reports By FirstWord

Found 469 publications
Colorectal Cancer KOL Insight 2016 US$ 7,900.00 Oct, 2016
Market Access Impact: Myeloma (US) US$ 4,995.00 Oct, 2016
Market Access Impact: Myeloma (EU5) US$ 4,995.00 Oct, 2016
Ulcerative Colitis: KOL Insight US$ 7,900.00 Sep, 2016
The Future of Orphan Drugs US$ 695.00 Sep, 2016
Hepatitis C: KOL Insight US$ 7,900.00 Sep, 2016
The Real Value of Medical Affairs US$ 395.00 Sep, 2016
NPS+ Rheumatoid Arthritis (US) US$ 2,495.00 Sep, 2016
NPS+ Rheumatoid Arthritis (EU5) US$ 2,495.00 Sep, 2016
MAR T2DM (US) US$ 5,995.00 Aug, 2016
MAR T2DM (EU5) US$ 5,995.00 Aug, 2016
Patient Assistance Programs US$ 695.00 Aug, 2016
The Future of Market Access US$ 695.00 Aug, 2016
NSCLC: KOL Insight US$ 7,900.00 Aug, 2016
Digital Health Start Ups US$ 695.00 Jul, 2016
The Future of Biosimilars 2016 US$ 2,195.00 Jul, 2016
Psoriasis KOL Insight US$ 7,900.00 Jul, 2016
Multiple Sclerosis: Payer Insight US$ 7,900.00 Jul, 2016
1 2 3 4 5 ... 10
Skip to top

Analytics, News & Press-Releases by FirstWord